Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Tab.Cefixime 200 mg
Tab.Ivermectin 12 mg
Tab.Montelukast 10 mg
Syp.Ascoril LS 5 ml: Tab.Cefixime 200 mg BD for 5 days
Tab.Ivermectin 12 mg OD for day 1
Tab.Montelukast 10 mg OD for 5 da
Sponsors
Public Health Department
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients of both Gender aged more than 18 years old. 2.Willing and able to provide written informed consent. 3.Patients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV2 / COVID) infection confirmed by RT Polymerase chain reaction (RT-PCR) test 4.Currently hospitalized and requiring medical care for COVID-19 5.Peripheral capillary oxygen saturation (SpO2) > 94% on room air at screening
Exclusion criteria
Exclusion criteria: 1.Subjects having less than 18 years of age 2.Drug atopy subjects 3.Private positive patients/ Truenaat positive/ Antigen positive 4.Critical comorbities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compared to standard of treatment receiving in COVID -19 infection, proposed regimen if consumed as an add on therapy prescribed by physician as per the clinical conditions and disease outcome will be efficacious in reducing medically attended lung infection caused by RT-PCR-confirmed COVID-19 virus in COVID Positive adults more than age 18 yrs .Timepoint: 14 Days | — |
Secondary
| Measure | Time frame |
|---|---|
| There will be a reduction in the incidence of hospitalizations attributable to COVID-19 in patients treated with proposed regimen There will be minimal chances of respiratory failure in patients due to COVID-19 in patients treated with proposed regimen Timepoint: 14 days | — |
Countries
India
Contacts
Public ContactDr Dhananjay Lad
CROM Clinical Research & Medical Tourism Pvt. Ltd.
Outcome results
None listed